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Inhibition of U4 snRNA in Human Cells Causes the Stable
Retention of Polyadenylated Pre-mRNA in the Nucleus
Anne Hett, Steven West*
The Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh, United Kingdom
Abstract
Most human pre-mRNAs contain introns that are removed by splicing. Such a complex process needs strict control and
regulation in order to prevent the expression of aberrant or unprocessed transcripts. To analyse the fate of pre-mRNAs that
cannot be spliced, we inhibited splicing using an anti-sense morpholino (AMO) against U4 snRNA. As a consequence,
splicing of several selected transcripts was strongly inhibited. This was accompanied by the formation of enlarged nuclear
speckles containing polyadenylated RNA, splicing factors and the nuclear poly(A) binding protein. Consistently, more
polyadenylated pre-mRNA could be isolated from nucleoplasmic as well as chromatin-associated RNA fractions following U4
inhibition. Further analysis demonstrated that accumulated pre-mRNAs were stable in the nucleus and that nuclear RNA
degradation factors did not re-localise to nuclear speckles following splicing inhibition. The accumulation of pre-mRNA and
the formation of enlarged speckles were sensitive to depletion of the 39 end processing factor, CPSF73, suggesting a
requirement for poly(A) site processing in this mechanism. Finally, we provide evidence that the pre-mRNAs produced
following U4 snRNA inhibition remain competent for splicing, perhaps providing a biological explanation for their stability.
These data further characterise processes ensuring the nuclear retention of pre-mRNA that cannot be spliced and suggest
that, in some cases, unspliced transcripts can complete splicing sometime after their initial synthesis.
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Introduction
Most human pre-mRNAs contain multiple introns that are
removed by splicing. The splicing process involves five small
nuclear (sn) RNAs and well over a hundred associated factors [1].
It begins with base pairing between U1 snRNA and the 59 splice
site. Subsequently, the 39 splice site is recognised by U2AF35 and
65 before U2 snRNA base-pairs with the branch-point. U4, U5
and U6 snRNAs are then recruited before rearrangements within
the spliceosome release U1 and U4 prior to the first catalytic step.
This results in the formation of a downstream lariat exon and
release of the upstream exon. The two exons are ligated during the
second step of splicing and the intron lariat is de-branched and
degraded. In higher eukaryotes, splicing is thought to occur by
exon definition whereby splice sites are recognised through
interactions occurring across exons rather than over the much
longer introns [2]. In this model, the removal of the first and final
intron involves the 59 cap and the cleavage and polyadenylation
signal, respectively [3–6].
Splicing is also tightly coupled to transcription by RNA
polymerase II (Pol II) [7]. Several recent reports demonstrated
that the majority of introns are removed co-transcriptionally
before Pol II terminates transcription [8-12]. There is a general
polarity to this process such that 59 introns are more frequently
subject to co-transcriptional splicing with some 39 introns removed
after processing at the poly(A) site [9–11,13,14]. Mechanistically,
this is because 39 end processing requires prior recognition of the
terminal 39 splice site but not removal of the intron [15]. The
multiple studies showing that splicing is mostly co-transcriptional
are corroborated by findings that the majority of activated
spliceosomes co-purify with chromatin [16]. The active spliceo-
somes that are nucleoplasmic are present in speckles that also
contain the splicing factor, SC35 [16].
SC35 speckles contain many factors involved in pre-mRNA
processing, particularly splicing [17,18]. It is generally accepted
that Pol II is not enriched within speckles but it has been found at
their periphery [19,20]. It was also demonstrated that pre-mRNAs
associate with speckles in an intron-dependent manner and that
splicing could occur in these regions [21]. Consistent with an
association between speckles and intron removal, small molecule
inhibitors of splicing induce the appearance of enlarged nuclear
speckles containing both polyadenylated RNA and SC35 [22–24].
Polyadenylated mRNA also accumulates in speckles following
depletion of factors involved in its export [16,21]. Indeed, splicing
is required for the export of intron-containing pre-mRNA through
deposition of the Exon Junction Complex (EJC) and the export
factor TAP [25–30]. SC35 speckles therefore constitute sites of
splicing factor storage, in which pre-mRNA processing and final
steps in mRNP remodelling can take place prior to export into the
cytoplasm.
As would be expected for such a complex and fundamental
process, splicing is subject to strict nuclear quality control. This
was first observed in budding yeast where mutations in either the
exosome complex or Rat1 cause unspliced precursor RNAs to
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accumulate, with the exosome playing the major role in their
degradation [31,32]. In human cells, the Rrp6 component of the
nuclear exosome as well as the Rat1 homologue Xrn2 are also
involved in the quality control of transcripts when splicing is
impaired, either by mutation or through treatment with
Spliceostatin A (SSA) [33–35]. Interestingly, SSA also promotes
a major increase in the level of some unspliced pre-mRNAs, which
are not targeted by either Rrp6 or Xrn2 [24,33,36]. Instead, they
have been observed to accumulate as polyadenylated species in the
nucleoplasm of cells with a certain proportion leaking into the
cytoplasm to be translated [22–24,37]. It is not established why
these transcripts are not subject to rapid nuclear degradation.
We have studied the fate of transcripts that accumulate
following blocks to splicing using a morpholino (AMO) directed
to U4 snRNA, which we show to inhibit splicing in a dose-
dependent manner. Like small molecule splicing inhibitors, U4
AMO treatment causes polyadenylated RNA to accumulate in
nuclear speckles together with SC35 and nuclear poly(A) binding
protein (PABPN1). We also detect a substantial increase in the
abundance of several polyadenylated pre-mRNAs in both the
chromatin and nucleoplasmic fractions isolated from U4 AMO
treated cells. These transcripts remain stable in the nucleus
following prolongued transcription inhibition and nuclear exori-
bonucleases do not concentrate in speckles following splicing
blocks. We show that inhibition of 39 end cleavage and
polyadenylation impairs pre-mRNA accumulation and speckle
formation following splicing inhibition. Finally, we provide
evidence that some unspliced pre-mRNAs, produced in cells
where U4 snRNA is partially inhibited, are capable of delayed
splicing. These data uncover processes ensuring the stable nuclear
retention of unprocessed RNA following splicing inhibition.
Materials and Methods
Primers, siRNAs and Morpholinos
Intronless transcripts
c-Jun F CCCCAAGATCCTGAAACAGA
c-Jun R CCGTTGCTGGACTGGATTAT
GLUD2 F GAATCCATGGACGCATCTCT
GLUD2 R TCCCATCAGACTCACCAACA
TAF7 F CTCCTCACGAACTGGAGAGC
TAF7 R CCATAACACAGGGCAGGTCT
U12 intron containing transcript
FAM96B splF ATGCCAACCCCCTCATCTAC
FAM96B splR AACCCGCACCTGCTCTACTA
FAM96B usF ATGCCAACCCCCTCATCTA
FAM96B usR AGCGGCGGATATCGAAGAT
U2 intron containing transcripts
P27 splF AATGCGCAGGAATAAGGAAG
P27 splR ATTTGGGGAACCGTCTGAA
P27 usF GCTAACATACTGACAAAATAATTCCTG
P27 usR CATGTATATCTTCCTTGCTTCATCA
Myc splF GAGGCTATTCTGCCCATTTG
Myc splR CACCGAGTCGTAGTCGAGGT
Myc usR CTCTGACCTTTTGCCAGGAG
Myc usF CCAGGCTTAGATGTGGCTCT
Myc UCPA FGGCAAATATATCATTGAGCCAA
Myc UCPA RCCCAGACCCATTTCAACAGA
ETF1 usF TGCAAGAGAATAGGGCTTCC
ETF1 usR CGGACCCATGTCGACTACCT
ETF1 splF ACAGGAACGTGGAGATCTGG
ETF1 splR CAGGACTGAAAGGCGGTTTA
HSPA9 usF GGAGGGGGAGTGGAATAGAA
HSPA9 usR AGAGCCTTCTCGCTCAGATG
HSPA9 splF GCAATCAAGGGAGCAGTTGT
HSPA9 splR GTCGCTCACCATCTGCTGTA
Histone
Hist1E F TTCAACATGTCCGACTGC
Hist1E R AGGCGGCAACAGCTTTAGTA
U6 snRNA
U6 F ACATATACTAAAATTGGAACGATAC
U6 R GGAACGCTTCACGAATTTGCGT
AMOs
Control CCTCTTACCTCAGTTACAATT-
TATA
U4 TACGATACTGCCACTGCG
CAAAGCT
U6 CCATGCTAATCTTCTCTG
TATCGTT
U6atac AACCTTCTCTCCTTTCATACAA
CAC
siRNAs
Control Life technologies silencer negative control #1
CPSF73 Life technologies silencer select s28533
Cell culture
Cells were grown in DMEM supplemented with 10% foetal calf
serum. Electroporation of AMOs (10 nmol unless otherwise stated)
was performed on a confluent 10 cm diameter dish of cells in
400 ml DMEM using a 4 mm gap cuvette (960 mF, 280 v in a
Biorad gene pulser). RNA was isolated three hours after
electroporation unless cells were subsequently treated. For
transient transfection 2–3 mg of plasmid was transfected using
JetPrime (Polyplus) and experiments were performed 48 hours
later. For RNAi, 20% confluent 60 mm dishes were transfected
with 18 ml of 2 mM siRNA and 5 ml RNAiMAX (Life Technol-
ogies) and left for 72 hours. The transfection was repeated after re-
plating of cells to 20% confluence and RNA/protein was isolated
after a further 48 hours. Actinomycin D was used at a final
concentration of 10 mg/ml, Cordycepin was used at 50 mg/ml for
2 hours and Pladienolide B was used at a concentration of 1 mM
for 3 hours.
Antibodies
CPSF73 (Sigma, C2747), Tubulin (Sigma, T6557), PABPN1
(Abcam, 75855), SC35 (Sigma, 4045), Dbr1 (Proteintech, 16019-1-
AP), Pol II Serine 2-P (Chromotek, 3E10), Pol II H224 (Santa
Cruz, sc-9001x), U2AF65 (Sigma, U4758), Anti flag (Sigma, MS2),
Rrp6 (Abcam, 50558).
RNA analysis
Total RNA was isolated using Trizol (Life Technologies) and
DNase treated with Turbo DNase (Life Technologies). Isolation of
chromatin-associated and nucleoplasmic RNA is described in
detail elsewhere [33]. For real-time PCR analysis, 1 mg RNA was
reverse transcribed using Inprom II (Promega). Parallel reactions
were performed in the absence of reverse transcriptase to control
for DNA contamination. 1/20th of the cDNA mix was used for
real-time PCR using 5–10 pmol of forward and reverse primer
and Brilliant III SYBR mix (Agilent Technologies) in a Qiagen
Rotorgene machine. Differences were calculated using compara-
tive quantitation.
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Microscopy
For immunofluorescence (IF) of proteins, cells grown on cover
slips were fixed with 3.7% formaldehyde (10 min) and permea-
bilised by incubation with 0.5% Triton X 100 in PBS (10 min).
After three short washes with PBS, cells were blocked for 1 hour
with 10% goat serum (Life Technologies) and incubated with
primary antibody in 10% goat serum. Following three more
washes, they were incubated with the secondary antibody in 10%
goat serum for 1 hour. Finally, after 3 further washes with PBS
cover slips were mounted (gold anti-fade, Life Technologies) and
sealed. For FISH, cells were grown, fixed and permeabilised as for
IF and then equilibrated with 30% Formamide in 26 SSC
(2615 min). They were then hybridised with the probe over night
at 37uC in a humid chamber (30% Formamide, 0.02% BSA,
0.1 mg/ml tRNA, 10% Dextran Sulphate, 30 ng probe, 2xSSC,
0.5 ml RNase Inhibitor). Cells were washed and mounted as for IF.
Figure 1. A. Diagram depicting primer pairs used to analyse spliced (spl) and unspliced (us) pre-mRNA. Exons are black boxes. B. Quantitation of P27
and Myc splicing in cells treated with the indicated amounts of U4 AMO. Splicing inhibition was calculated as a ratio of signal for unspliced versus
spliced RNA and expressed as a fold change compared to cells treated with control AMO (0 nmol U4 AMO). Intronless TAF7 transcripts were analysed
as a control. C. Quantitation of unspliced P27, Myc, HSPA9 and ETF1 pre-mRNA, spliced Myc, HSPA9 and ETF1 mRNA, intronless c-Jun, TAF7 and
GLUD2 and minor spliceosome-dependent FAM96B splicing in cells treated with control or 10 nmol U4 AMOs. Results are expressed as a fold change
over values obtained in control cells after normalising to Histone H1E levels. D. Quantitation of FAM96B and Myc splicing in cells treated with control
or U6atac AMOs. Values are expressed as a fold change over values obtained in control cells after normalising to Histone H1E levels.
doi:10.1371/journal.pone.0096174.g001
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For 5-Ethynyl Uridine (EU) labelling, electroporated cells were
incubated with 0.5 mM EU (Life technologies), washed and
permeabilised as for IF. Subsequently, click ligation was performed
using a Click-IT kit as per the manufacturers’ guidelines (Life
Technologies). Cells were mounted and visualised as for IF. All
pictures were obtained using a Deltavision Elite (Applied
Precision, Issaquah Washington) microscope and either a Cool-
snap HQ (Photometrics UK, Marlow, Bucks) or Cascade II
EMCCD (Photometrics UK, Marlow, Bucks) camera. The
microscope was equipped with an x100 PlanAPO NA 1.4
(Olympus UK) objective. The deconvolution software used was
Softworx (Applied Precision, Issaquah Washington).
Results
A U4 AMO is a potent and dose-dependent inhibitor of
pre-mRNA splicing
We previously described the use of an anti-sense morpholino
(AMO) directed to U4 snRNA that acts as an efficient splicing
inhibitor in vivo [15]. Prior to spliceosome activation, U4 is
extensively base-paired with U6 which sequesters the catalytic
activity of the latter [15,38–40]. The region of U4 that forms stem
II of this interaction is crucial for splicing in vitro [41,42]. Our U4
AMO is designed to block the interaction between U4 and U6 by
preventing the formation of stem II and therefore inhibiting the
production of active spliceosomes. In so doing, pre-mRNAs can
assemble U1 and U2 complexes but splicing is blocked prior to
catalysis [15,42]. The use of AMOs to inhibit splicing is
advantageous over protein knock-down by RNAi because they
act much more rapidly (3 hours versus typically 72 hours),
somewhat limiting off-target effects.
We wished to use this reagent to study the consequences of
splicing inhibition in vivo. Although we have previously demon-
strated its effectiveness as a splicing inhibitor at the RNA level
[15], we had not studied the fate of the resulting pre-mRNAs. To
begin with, we assessed the dose-dependence of its effect on intron
removal. HeLa cells were electroporated with increasing amounts
of U4 AMO (0.5–20 nmol) or 10 nmol of control AMO (0 nmol
U4 AMO). Total RNA was then isolated after 3 hours to limit off-
target effects. Following reverse transcription with random
hexamers, real-time PCR was performed using primers that
detect intron-containing and spliced P27 or Myc transcripts
(Figure 1A). We chose these transcripts as they accumulate
markedly in cells where splicing is inhibited [15,24,33]. Splicing
Figure 2. A. FISH and IF to detect polyadenylated RNA or PABPN1 respectively in cells electroporated with control AMO or the indicated amounts of
U4 AMO. Scale bar is 5 mm. B. Graph showing the percentage of cells displaying an enlarged speckle phenotype under conditions of increased U4
AMO concentrations. 100 cells were counted per condition over three separate experiments. C. EU labelling of nascent RNA and IF of SC35 in cells
treated with control or 10 nmol U4 AMO. Scale bar is 5 mm.
doi:10.1371/journal.pone.0096174.g002
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was then plotted as a ratio of unspliced versus spliced product
(Figure 1B). Significant splicing impairment was observed with
1 nmol AMO (,4-fold); however inhibition was progressively
more substantial with 20 nmol U4 AMO inducing a 50–100 fold
inhibition of splicing for both of these transcripts. Thus, the U4
AMO is a powerful inhibitor of splicing that acts in a dose-
dependent manner.
Next, we assessed the effect of U4 AMO treatment on a range of
transcripts additional to those from MYC and P27 genes
(Figure 1C). To this end, total RNA was isolated from cells
treated with 10 nmol of control or U4 AMO and reverse
transcribed with random hexamers. Since P27 and MYC genes
are relatively short and contain only two introns, we measured
spliced and unspliced transcripts from two longer genes that
contain multiples introns: ETF1 and HSPA9. To verify the
specificity of U4 AMO treatment towards U2-dependent splicing,
transcripts from three intron-less genes (TAF7, c-JUN and GLUD2)
and a splicing event performed by the minor U12-dependent
spliceosome (that of FAM96B pre-mRNA intron 1) was assayed.
As expected, a substantial increase in the level of unspliced Myc
and P27 RNA was again evident with a reduction in spliced Myc
also observed. Similar effects were observed for ETF1 and HSPA9
transcripts. However, the levels of intron-less transcripts were
unaffected and FAM96B intron 1 showed no evidence of increased
retention. These data strongly suggest that the U4 AMO affects
the splicing of transcripts that are substrates for the U2-dependent
spliceosome but not the level of intron-less or minor-spliceosome
dependent RNAs.
As a final specificity control for the AMO approach, we elected
to inhibit the minor spliceosomal U6atac snRNA. We treated cells
with a control AMO or an AMO directed to the U6atac snRNA
[43]. Total RNA was again reverse transcribed with random
hexamers and real-time PCR was used to detect spliced and
unspliced Myc transcripts as well as to assess splicing of FAM96B
intron 1 (Figure 1D). The U6atac AMO did not affect Myc pre-
mRNA splicing, which was expected since its splicing depends on
the major spliceosome. However, it caused an accumulation of
FAM96B intron 1 with a concomitant reduction in the
corresponding spliced product. We conclude that the U4 AMO
inhibits splicing by the major spliceosome and the U6atac AMO
inhibits the minor splicing pathway. These data highlight the
specificity and potency of the U4 AMO-based approach to inhibit
splicing.
Splicing inhibition induces the formation of enlarged
nuclear speckles containing polyadenylated RNA
Previous studies demonstrated that treating cells with the small
molecule splicing inhibitors Meayamycin (MY) and Spliceostatin
A (SSA) induced the accumulation of polyadenylated RNA in
enlarged nuclear speckles [22–24]. These compounds inhibit
splicing after U1 and U2 snRNAs are recruited to the intron and
specifically target the SF3b complex [24,44–47]. We were
interested to see whether inhibition of U4 snRNA might cause a
similar enlargement of nuclear speckles even though SF3b would
not be directly targeted. To test this, we electroporated cells with
increasing amounts of U4 AMO or 10 nmol of control AMO
(0 nmol U4 AMO) and tested the location of polyadenylated RNA
and the nuclear poly(A) binding protein, PABPN1, by fluorescence
in situ hybridisation (FISH) and immunofluorescence (IF) respec-
tively (Figure 2A). Similar to MY and SSA, treatment of cells with
the U4 AMO caused polyadenylated RNA to accumulate in
enlarged nuclear speckles. The same was true for PABPN1. As the
concentration of AMO was increased, more cells displayed this
phenotype confirming its dose-dependence (Figure 2B). Finally,
Pladienolide B (PB), an established SF3b inhibitor, gave the same
result as did an AMO directed to U6 snRNA (Figure S1).
We next wished to determine if this polyadenylated RNA
represented a major or a minor fraction of transcripts that were
redistributed following splicing inhibition. To do this, cells were
electroporated with control or U4 AMOs and growing cells were
subjected to metabolic labelling using 5-Ethynyl Uridine (EU). EU
will detect all synthesised transcripts rather than only polyadenyl-
Figure 3. A. IF of SC35 and PABPN1 in cells treated with control or U4 AMO. Scale bar is 5 mm. B. IF of PABPN1 and U2AF65 in cells treated with
control of U4 AMO. Scale bar is 20 mm. C. IF of total Pol II (H224) and SC35 in cells treated with control or U4 AMO. Scale bar is 5 mm. D. IF of Dbr1 and
Pol II phosphorylated on Serine 2 (Pol II S2P) in cells treated with control of U4 AMO. Scale bar is 5 mm.
doi:10.1371/journal.pone.0096174.g003
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ated RNA. Cells were subsequently labelled with Alexa Fluor 594
by a click reaction and visualised (Figure 2C). In both control and
U4 AMO treated cells, the majority of signal was present in
nucleoli consistent with the high level of rRNA transcription that
occurs in cells. However, there was an additional concentration of
EU RNA in enlarged speckles outside of the nucleolar region in
U4 AMO treated cells but not in control cells. Importantly, these
enlarged regions overlapped with that of the well characterised
speckle marker SC35, as determined by IF. Together, the FISH
and IF data in Figure 2 show that polyadenylated RNA
accumulates in enlarged PABPN1 and SC35-containing nuclear
speckles when splicing is inhibited by a U4 AMO. The fact that
U4 AMO specifically inhibits U2-dependent splicing suggests that
some of the RNA within speckles is pre-mRNA. Indeed, an AMO
against U6atac snRNA did not induce this phenotype presumably
due to the small number of splicing events that are inhibited
(Figure S2).
Enlarged speckles contain U2AF65 but not active RNA
polymerase II
To characterise the enlarged nuclear speckles further, we
performed a limited IF analysis of additional factors to test their re-
localisation, if any, following splicing inhibition by the U4 AMO.
We first confirmed that PABPN1 and SC35 were co-localised in
enlarged speckles after U4 AMO treatment (Figure 3A). Next, we
assayed the U2AF65 splicing factor (Figure 3B, Figure S3A).
U2AF65 became concentrated in enlarged nuclear speckles
together with PABPN1 following U4 AMO treatment. This is
consistent with the expectation that U4 AMO blocks splicing
following U1 and U2 snRNA recruitment.
We next sought to determine whether Pol II, or factors that
would be expected to act after U4 snRNA in the splicing process,
would accumulate in enlarged speckles following splicing inhibi-
tion. We first performed IF on total Pol II (H224) (Figure 3C,
Figure S3B). Signal was observed throughout the cell with a
Figure 4. A. Isolation of chromatin-associated and nucleoplasmic RNA from cells treated with control or U4 AMO. Spliced (spl), unspliced (us) and
non-pA cleaved (ucpa) Myc transcripts are detected. Following normalisation to intronless c-Jun RNA, values are plotted as a fold change compared
to the chromatin-associated fraction of control cells (given a relative value of 1). B. Isolation of chromatin-associated and nucleoplasmic RNA from
cells treated with control or U4 AMO. Unspliced and polyadenylated Myc, P27, HSPA9 and ETF1 transcripts are detected. Following normalisation to
intronless c-Jun RNA, values are plotted as a fold change compared to the chromatin-associated fraction of control cells (given a relative value of 1).
doi:10.1371/journal.pone.0096174.g004
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noticeable enrichment within the nucleus. However, contrary to
SC35, it was not dramatically re-localised following U4 AMO
treatment suggesting that enlarged speckles do not represent sites
of transcription. Next, we analysed transcriptionally active Pol II
phosphorylated on Serine 2 of its C-terminal domain (Pol II S2P)
as well as the debranching enzyme Dbr1, which is required after
U4 function in splicing (Figure 3D, Figure S3C). Although U4
AMO caused a reduction in Pol II S2P signal, it did not promote
its localisation to enlarged speckles. This again suggests that there
is little or no transcription within the nuclear speckles and that
therefore the RNA within them is not nascent. Similarly, Dbr1 was
also broadly distributed within the nucleus but did not localise to
nuclear speckles following U4 AMO treatment. This is consistent
with the fact that it functions subsequently to U4 snRNA in the
splicing process. Thus, enlarged nuclear speckles observed
following U4 inhibition contain proteins that act prior to U4
snRNA in splicing, as well as PABPN1 presumably due to the
polyadenylated nature of the transcripts. However, Dbr1 and Pol
II are not concentrated within the enlarged speckles.
U4 AMO treatment causes the accumulation of
polyadenylated pre-mRNA in chromatin and
nucleoplasmic RNA fractions
Data so far show that U4 AMO inhibits splicing and causes
polyadenylated RNA to accumulate in enlarged nuclear speckles.
To quantitate the effects of U4 AMO on pre-mRNA levels and
their distribution within the nucleus, we used a well-characterised
Figure 5. A. IF of EGFP-Mtr4 and PABPN1 in cells treated with control or U4 AMO. Scale bar is 5 mm. B. IF of EGFP-Rbm7 and PABPN1 in cells treated
with control or U4 AMO. Scale bar is 5 mm. C. IF of Flag-Xrn2 and PABPN1 in cells treated with control or U4 AMO. Scale bar is 15 mm. D. IF of Rrp6 and
SC35 in cells treated with control or U4 AMO. Scale bar is 5 mm. E. FISH and IF to detect polyadenylated RNA and SC35 in cells treated with control or
U4 AMO followed by 2 hours in the presence of Act D or ethanol (Control). Scale bar is 15 mm. F. Real-time PCR analysis of polyadenylated and
unspliced Myc, P27, HSPA9 and ETF1 transcripts in the nuclear and cytoplasmic fractions of cells electroporated with control (C) and U4 AMO and
subsequently treated with Act D or ethanol (use of Act D is indicated below x-axis). Quantitation is shown as fold change compared to amounts
found in the nuclei of control AMO treated cells after ethanol treatment, which were given a value of 1.
doi:10.1371/journal.pone.0096174.g005
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method to biochemically isolate chromatin-associated and nucle-
oplasmic transcripts from nuclei [48]. This was done in cells
treated with control or U4 AMOs and isolated RNA was reverse
transcribed with random hexamers. To verify efficient separation
of the two fractions, we monitored the level of spliced, unspliced
and non-pA cleaved Myc RNA (Figure 4A). As previously
observed [9,12,33,49], spliced transcripts were more enriched in
the nucleoplasm compared to chromatin and were depleted in
samples from U4 AMO treated cells. Unspliced RNA was
predominantly chromatin-associated in control cells in agreement
with the view that pre-mRNA processing is normally coupled to
transcription. An increase in unspliced RNA was seen in both
chromatin-associated and nucleoplasmic fractions following U4
treatment as expected. This is similar to previous findings from our
laboratory and suggests that while some unspliced transcripts are
retained on chromatin following splicing inhibition, a proportion is
released [15]. Finally, non-pA cleaved RNA was predominantly
chromatin-associated in both control and U4 treated cells and was
unaffected by splicing inhibition. As well as being consistent with
our previous finding that poly(A) site cleavage is unaffected by U4
inhibition [15], this provides evidence that unspliced transcripts
accumulating in the nucleoplasm are cleaved at their poly(A) site.
Accordingly, we next assayed the distribution of polyadenylated
unspliced RNA within nuclei of control and U4 AMO treated
cells. Chromatin-associated and nucleoplasmic RNA from these
cells was reverse transcribed with oligo-dT before detection of
unspliced P27, Myc, ETF1 and HSPA9 transcripts by real time
PCR (Figure 4B). Unspliced, polyadenylated pre-mRNA was
increased in both fractions in U4 AMO treated samples as
compared to those isolated from control cells. This confirms that
some unspliced pre-mRNA is polyadenylated. Furthermore, the
presence of these species in the nucleoplasm following splicing
inhibition is consistent with the appearance of enlarged speckles
enriched in polyadenylated RNA under the same conditions.
Finally, transcripts from the P27 and Myc genes accumulated
more markedly in the nucleoplasmic fraction than those from the
longer HSPA9 and ETF1 genes following U4 AMO treatment.
This may suggest transcript-specific regulation regarding the
release of unspliced pre-mRNA from chromatin.
Nuclear degradation machinery does not concentrate in
speckles following splicing inhibition
The accumulation of pre-mRNA transcripts following U4 AMO
treatment is dramatic suggesting that they are not rapidly
degraded. Indeed, we have previously shown that following SSA
treatment, some pre-mRNAs accumulate and are not affected by
depletion of nuclear exoribonucleases suggesting that they are not
degraded despite their inability to be spliced [33]. To gain more
understanding of the resistance of these unspliced transcripts to
degradation, we analysed the cellular distribution of major nuclear
RNA decay factors in control and U4 AMO treated cells. We
performed IF following over-expression of GFP-tagged core
nuclear exosome component Mtr4 in control and U4 AMO
treated cells (Figure 5A, Figure S4A). This protein was found
throughout the nucleus, including nucleoli where it was previously
observed [50]. The more homogeneous nuclear signal that we
observed might be due to the fixation of cells necessary for this co-
localisation experiment or electroporation of AMOs [51]. How-
ever, while U4 AMO treatment caused accumulation of PABPN1
in enlarged speckles there was no similar concentration of GFP-
tagged Mtr4 in the same cells. A similar result was obtained with
GFP-tagged Rbm7, a nuclear exosome co-factor that does not
localise to nucleoli [50] (Figure 5B, Figure S4B). We also tested the
effect of U4 AMO on the localisation of over-expressed Xrn2,
which is the major nuclear 59R39 exonuclease. While PABPN1
was concentrated in enlarged speckles following U4 AMO
treatment, Xrn2 did not (Figure 5C, Figure S4C). These data
indicate that over-expressed tagged exonucleases do not concen-
trate in nuclear speckles when splicing is inhibited under these
experimental conditions.
Because the above results were obtained using tagged and over-
expressed factors, we asked whether the localisation of an
endogenous exoribonuclease was affected by U4 AMO treatment
(Figure 5D, Figure S4D). We analysed the Rrp6 component of the
nuclear exosome, which has a well characterised role in pre-
mRNA quality control in budding yeast and humans [31,35,52].
Moreover, Rrp6 is involved at the interface between polyadenyl-
ation and degradation [52–54]. In control AMO treated cells,
Rrp6 was predominantly localised to nucleoli as previously
reported and consistent with its function in rRNA processing
[50,55,56]. This pattern was essentially unchanged following U4
AMO treatment showing that Rrp6 does not re-localise to
enlarged nuclear speckles following splicing inhibition. In contrast,
SC35 was localised to enlarged speckles in the same samples.
These data indicate that exonucleases do not re-localise to
enlarged nuclear speckles following U4 AMO treatment. It is
consistent with the observation in Figure 4 that pre-mRNAs
accumulate in the nucleoplasm as well as the chromatin following
U4 AMO treatment.
Unspliced pre-mRNA is stable within the nucleus
following transcription inhibition
Some leakage of unspliced transcripts into the cytoplasm occurs
in SSA treated cells [24,37]. However, it is not clear if transcripts
that are observed in speckles can eventually be exported or not. To
test this, we performed FISH and IF on polyadenylated RNA and
SC35, respectively, using cells electroporated with control or U4
AMO. Following this, cells were treated or not for two hours with
the transcriptional inhibitor, Actinomycin D (Act D). As can be
seen in Figure 5E, U4 AMO treatment caused polyadenylated
RNA and SC35 to accumulate in enlarged speckles as expected.
However, this was still the case after Act D treatment suggesting
that bulk polyadenylated RNA is nuclear-restricted following U4
AMO treatment rather than exported or degraded over the period
of transcription inhibition.
FISH and IF signal within enlarged speckles were sometimes
more diffuse after Act D treatment, which potentially complicates
the interpretation of these experiments (Figure S4E). Therefore,
we directly analysed individual pre-mRNA transcripts in nuclear
and cytoplasmic RNA fractions from control and U4 AMO
treated subsequently treated with Act D or, as a control, its ethanol
solvent. Following reverse transcription with oligo-dT, RNA was
real-time PCR amplified to detect unspliced Myc, P27, ETF1 and
HSPA9 transcripts (Figure 5F). In cells treated with control AMO
these were mainly nuclear and Act D treatment caused their
depletion confirming that transcription was inhibited. In U4 AMO
treated cells, unspliced pre-mRNA accumulated in the nucleus as
expected; however, after Act D treatment the majority of this
signal remained nuclear. This suggests that a large proportion of
polyadenylated pre-mRNA that accumulates in the nucleus
following U4 AMO treatment is retained there stably, at least
under the conditions used here.
Enlarged speckles do not form when cleavage and
polyadenylation are inhibited
Data so far suggest that inhibition of U4 snRNA causes
accumulation of unspliced, polyadenylated pre-mRNA in the
Inhibition of U4 snRNA in Human Cells
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nucleus and the appearance of enlarged nuclear speckles. We next
wanted to address the mechanistic basis for these two observations
and began by investigating the role of 39 end processing since
poly(A) site cleavage is well known to be required to both release
RNA from chromatin and stabilise it [57,58]. We depleted the 39
end processing endonuclease, CPSF73, from HeLa cells
(Figure 6A). Cells were next treated with control or CPSF73
specific siRNAs and then electroporated with control or U4
AMOs before visualisation of polyadenylated RNA by FISH. In
control siRNA treated cells, the U4 AMO induced accumulation
of these transcripts in speckles as observed before (Figure 6B).
However, U4 AMO treatment of CPSF73 depleted cells did not
have this effect and speckles were smaller and more numerous.
It might be expected that polyadenylated RNA signals would be
diminished following CPSF73 depletion due to disruption of
poly(A) site processing. Therefore we also monitored speckle
formation using IF to detect SC35 in control and CPSF73
depleted cells treated with control or U4 AMOs (Figure 6C, Figure
S5A). As before, U4 AMO treatment of control cells induced the
accumulation of SC35 in enlarged speckles. However, when
CPSF73 depleted cells were treated with the U4 AMO, SC35 did
not show this dramatic re-localisation. This experiment suggests
that the formation of enlarged nuclear speckles in U4 AMO
treated cells requires CPSF73 activity. The formation of enlarged
nuclear speckles was similarly abrogated by inhibiting polyade-
nylation (Figure S5B and S5C).
The above experiments suggest that cleavage and polyadenyl-
ation are critical for the formation of enlarged nuclear speckles.
Given the confirmed stabilising role for a poly(A) tail we also
wondered whether CPSF73 depletion might impair the general
Figure 6. A. Western blotting of CPSF73 (top panel) and Tubulin (lower panel) in cells treated with control or CPSF73 siRNAs. B. FISH analysis of
polyadenylated RNA in cells treated with control or CPSF73 siRNAs and, subsequently, with control or U4 AMO. Scale bar is 5 mm. C. IF of SC35 in cells
treated with control or CPSF73 siRNAs and, subsequently, with control or U4 AMO. Scale bar is 5 mm. D. Quantitation of non-poly(A) site cleaved Myc
transcripts in cells treated with control or CPSF73 siRNAs and, subsequently, with control or U4 AMO. Values are expressed as a fold change
compared to control siRNA transfected cells treated with control AMO after normalising to U6 snRNA. E. Quantitation of unspliced Myc transcripts
(intron 2-exon3) in cells treated with control or CPSF73 siRNAs and, subsequently, with control or U4 AMO. Values are expressed as a fold change
compared to control siRNA transfected cells treated with control AMO after normalising to U6 snRNA.
doi:10.1371/journal.pone.0096174.g006
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accumulation of unspliced pre-mRNA following U4 AMO
treatment. To test this, we isolated total RNA from both control
and CPSF73 depleted cells treated with control or U4 AMO
(Figure 6D). cDNA was then generated with random hexamers.
To confirm that CPSF73 depletion was sufficient to impair poly(A)
site cleavage we used primers spanning the Myc poly(A) site to
detect transcripts on which 39 end processing had not occurred. 3–
4 fold more of this transcript was recovered in samples from
CPSF73 depleted cells indicating that knock-down was sufficient to
disrupt cleavage and polyadenylation. This was the case in both
control and U4 AMO treated cells indicating that splicing
inhibition does not influence the function of CPSF73 in poly(A)
site cleavage.
Next we monitored the accumulation of unspliced Myc
transcripts in all four samples (Figure 6E). In cells treated with
control siRNA, U4 AMO caused a large accumulation of this
species as expected. However, fewer unspliced RNAs accumulated
in CPSF73 depleted cells treated with U4 AMO indicating that
cleavage and polyadenylation stabilises unspliced RNA. A
requirement for cleavage and polyadenylation for speckle forma-
tion and pre-mRNA accumulation may be explained by 39 end
processing being necessary to release RNA from chromatin into
speckle regions. However, knock-down of cleavage and polyade-
nylation may reduce transcription and pre-mRNA stability more
generally thus reducing the detectable poly(A)+ FISH signal as well
as the accumulation of selected pre-mRNAs such as Myc.
Figure 7. A. Act D time course analysis of unspliced Myc RNA (intron 2-exon 3) in cells treated with control AMO or 1 and 10 nmol U4 AMO. For each
condition, values are presented relative to levels present at time zero (given a value of 1). B. Act D time course analysis of non-pA cleaved Myc RNA in
cells treated with control AMO or 1 and 10 nmol U4 AMO. For each condition, values are presented relative to levels present at time zero (given a
value of 1).
doi:10.1371/journal.pone.0096174.g007
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Transcripts retain the ability to be spliced following U4
snRNA inhibition
We have shown that, following splicing inhibition, many pre-
mRNAs accumulate as polyadenylated transcripts in a manner
dependent on cleavage and polyadenylation. Although unpro-
cessed, these transcripts are not degraded. Recent work indicates
that some splicing occurs after 39 end processing and transcription
are completed [14,16]. Moreover, it has been proposed that some
of this splicing occurs in nuclear speckle domains [16,21]. We
wondered whether transcripts that accumulate following U4 AMO
treatment might somehow resemble processing intermediates that
can go on to be spliced, which might explain why they are not
degraded. If this is the case then transcripts whose splicing is
initially inhibited under these conditions might be capable of being
spliced in a delayed manner.
Unfortunately, AMOs and small molecule inhibitors of splicing
are not readily reversible somewhat confounding this analysis.
However, results in Figure 1 show that lower concentrations of U4
AMO inhibit splicing but in an incomplete manner. Results in
Figure 2 confirm that these concentrations are also sufficient to
induce the appearance of enlarged speckles containing polyade-
nylated RNA. This being the case, we wanted to establish whether
or not the unspliced transcripts that accumulate under these
conditions can still be spliced. Accordingly, we monitored the
levels of unspliced Myc transcripts (intron 2-exon 3) following
transcriptional inhibition by Act D (Figure 7A). We previously
showed that this species is rapidly depleted following Act D
treatment but not when U4 AMO was used, which confirms that
its loss depends on functional splicing [15,59]. We performed this
experiment on cells treated with control AMO or with 1 or
10 nmol of U4 AMO. Levels of Myc intron 2-exon 3 RNA were
determined by real-time PCR following reverse transcription. In
the control treated cells, this species was strongly reduced after 15
minutes of Act D treatment. As expected, this was due to
functional splicing because little reduction was observed in cells
treated with 10 nmol U4 AMO even after 2 hours. This
observation also highlights the stability of unspliced Myc following
U4 inhibition. In cells treated with 1 nmol of U4 AMO, much of
this species was depleted over the full time-course albeit at a slower
rate than in control cells. These data suggest that some delayed
splicing occurs in cells where U4 is partially inhibited.
It was next important to determine whether this delayed splicing
occurred after cleavage at the poly(A) site, which we have shown to
be required for optimal accumulation of unspliced pre-mRNA
following U4 AMO treatment. To test this, the Act D time course
was repeated to determine the rate of Myc poly(A) site cleavage.
Primers were used that span the Myc poly(A) site such that only
unprocessed transcripts were detected. Importantly, poly(A) site
cleavage precludes the detection of this species and so its loss is
indicative of processing (Figure 7B and [59]). As we had observed
previously, this species was lost equally rapidly in control cells and
cells treated with 10 nmol U4 AMO showing that intron removal
is not necessary for poly(A) site processing [15]. Treatment with
1 nmol U4 AMO gave a similar result whereby poly(A) site
cleavage occurred at the control rate. In sum, when compared to
control AMO treatment, splicing is substantially delayed relative
to poly(A) site cleavage in cells treated with 1 nmol U4 AMO.
These data argue that transcripts, for which splicing is initially
prevented by partial U4 AMO treatment, can still be spliced. This
is likely to occur after cleavage and polyadenylation, the rate of
which is unaffected by U4 inhibition. Similarly, it was shown that
depletion of the CDC5L splicing factor caused accumulation of
polyadenylated RNA within nuclear speckles [16]. However,
reintroduction of the CDC5L protein relieved this effect. These
findings suggest that some pre-mRNA transcripts that accumulate
in the nucleus following splicing inhibition are in a spliceable state,
which may explain their stability.
Discussion
Here we have explored the fate of transcripts produced in cells
where splicing is inhibited using a U4 AMO. Pre-mRNAs
accumulate as polyadenylated species coincident with the forma-
tion of enlarged nuclear speckles containing polyadenylated RNA.
Both the pre-mRNAs and speckle structures are stable and remain
present in nuclei following prolongued inhibition of transcription
by Act D. Consistent with their stability, we observe no re-
localisation of nuclear exonucleases within the nuclei of cells when
splicing is inhibited. Both pre-mRNA accumulation and speckle
formation were sensitive to inhibition of pre-mRNA cleavage and
polyadenylation arguing that 39 end processing plays an important
role in both events. We suggest that transcripts in cells defective for
splicing are stable at least in part because they remain splice-
competent. Consistently, unspliced transcripts that accumulate
when splicing is only partially inhibited can be spliced in a delayed
fashion.
An enlarged speckle phenotype like the one we see is also
observed when cells are treated with small molecule inhibitors of
splicing [22–24]. At least some of these transcripts are exported to
the cytoplasm because their aberrant protein products are
detectable [24]. Therefore, it is possible that the nonsense-
mediated decay pathway is the mechanism by which they are
eventually degraded. However, we observe high levels of
polyadenylated RNA in the nucleus following U4 AMO
treatment. Furthermore, this remains the case even after
transcription is inhibited. We therefore favour the interpretation
that some pre-mRNA is exported into the cytoplasm but a
substantial fraction is retained in the nucleus. This is consistent
with data demonstrating a strong link between splicing and mRNA
export [25,29,30].
We were unable to unequivocally localise an individual pre-
mRNA to the enlarged speckles using FISH (data not shown) even
though these domains were enriched in polyadenylated RNA.
Data in figure 4 support the idea of polyadenylated pre-mRNA
being part of the enlarged speckles by showing their accumulation
in nucleoplasmic RNA fractions from U4 AMO treated cells. Our
observation that only substrates for U2-dependent splicing are up-
regulated by U4 AMO treatment and that enlarged speckles only
form when splicing is inhibited also suggests that speckles contain
pre-mRNA. Moreover, the sensitivity of enlarged speckle forma-
tion to CPSF73 depletion suggests the presence of pre-mRNAs
there since the major function of this factor is in processing poly(A)
sites. Finally, others were able to localise b-globin pre-mRNA to
speckles when small molecules were used to inhibit splicing – albeit
for a longer period of time than we used [22,23]. Thus, although
we cannot exclude the presence of other polyadenylated RNAs in
enlarged speckles, we favour the view that a proportion of RNA
within them is pre-mRNA.
U4 AMO promotes the accumulation of pre-mRNA on
chromatin as well as in the nucleoplasm, coincident with the
appearance of enlarged speckles. This indicates two potential ways
that ultimately prevent the expression of unprocessed transcripts:
one that prevents their release from chromatin and another that
sequesters released transcripts within nucleoplasmic domains.
Interestingly, the proportion of pre-mRNA that is present in the
nucleoplasm following splicing inhibition differs among the
transcripts that we analysed being much higher for P27 and
Myc transcripts as compared to HSPA9 and ETF1. Further
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studies will be required to determine the basis of this observation
but it may well reflect transcript-specific requirements for
chromatin release. However, it is generally the case that the
majority of pre-mRNA is retained stably in the nucleus following
U4 AMO treatment. We would speculate that this is due to factors
that remain bound as a result of intron retention as well as the
absence of proteins that are normally deposited by splicing. The
former may include members of the U1 and U2 snRNPs, which
remain bound in cells treated with U4 AMO [15]. Indeed U1-70k
and U2AF65 are actively involved in pre-mRNA retention within
the nucleus [37]. The latter class of factors is likely to include EJC
components, which are bound following splicing and are required
for RNA export [29,60,61].
As well as being retained in the nucleus due to defects in the
normal pathway of mRNA biogenesis, unspliced pre-mRNAs
accumulating following U4 inhibition could be subject to active
quality control. Indeed, a variety of different quality control
pathways have been identified that promote turnover of unpro-
cessed or splice-defective RNA. However, the transcripts that we
have analysed following U4 inhibition are stable. We speculate
that this may be because they are recognised as being genuine
splicing precursors rather than aberrant pre-mRNAs. We propose
that early steps in spliceosome assembly must still take place in the
presence of U4 AMO because recognition of the terminal 39 splice
site is required for 39 end processing, which still occurs when U4 is
inhibited [3,15,62]. The fact that some delayed splicing may take
place when U4 is partially inhibited indicates that these early
assembly steps might be sufficient to license intron removal.
Furthermore, this observation supports the possibility that there
may not be a fixed window in which splicing must occur. As such,
when splicing is inhibited, unspliced pre-mRNAs may be released
from the transcription site and accumulate in speckles or elsewhere
where, under normal circumstances, splicing would be completed.
We have described mechanisms that prevent the export and
expression of pre-mRNA in cells where splicing is inhibited by a
U4 AMO. Rather than being degraded, these transcripts are very
stable and we provide evidence that they can be spliced at a later
time than normal. This pathway thus serves two useful purposes:
firstly, unprocessed transcripts are prevented from being exported
and secondly, transcripts that appear capable of being processed
are preserved such that they may later complete their nuclear
maturation.
Supporting Information
Figure S1 Pladienolide B or U6 AMO treatment results
in the accumulation of polyadenylated RNA within
enlarged nuclear speckles. A. IF of SC35 and PABPN1 in
cells treated with DMSO or the splicing inhibitor Pladienolide B
(PB). Scale bar is 20 mm. B. FISH and IF of polyadenylated RNA
and SC35 respectively in cells treated with DMSO or the splicing
inhibitor PB. Scale bar is 20 mm. C. FISH and IF of
polyadenylated RNA and SC35 respectively in cells treated with
control or U6 AMO (10 nmol). Scale bar is 5 mm.
(TIFF)
Figure S2 U6atac inhibition does not result in enlarged
nuclear speckles. A. IF of SC35 and PABPN1 in cells treated
with control or U6atac AMO (10 nmol). Scale bar is 15 mm. B.
FISH and IF of polyadenylated RNA and SC35 respectively in
cells treated with control or U6atac AMO (10 nmol). Scale bar is
15 mm.
(TIFF)
Figure S3 Alternative cell pictures accompanying main
text figure 3. A. IF of U2AF65 and PABPN1 in cells treated with
control of U4 AMO (10 nmol). Two panels are shown per
condition. Scale bar is 20 mm. B. IF of SC35 and total Pol II
(H224) in cells treated with control of U4 AMO (10 nmol). Two
panels are shown per condition. Scale bar is 5 mm. C. IF of Pol II
S2P and Dbr1 in cells treated with control of U4 AMO (10 nmol).
Two panels are shown per condition. Scale bar is 5 mm.
(TIF)
Figure S4 Alternative cell pictures accompanying main
text figure 5. A. IF of GFP-tagged Mtr4 and PABPN1 in cells
treated with control of U4 AMO (10 nmol). Two panels are shown
per condition. Scale bar is 5 mm. B. IF of GFP-tagged Rbm7 and
PABPN1 in cells treated with control of U4 AMO (10 nmol). Two
panels are shown per condition. Scale bar is 5 mm. C. IF of flag-
Xrn2 and PABPN1 in cells treated with control of U4 AMO
(10 nmol). Two panels are shown per condition. Scale bar is
15 mm. D. IF of SC35 and Rrp6 in cells treated with control of U4
AMO (10 nmol). Two panels are shown per condition. Scale bar is
5 mm. E. Poly(A)+ RNA FISH and SC35 IF in control (left-hand
panels) and U4 AMO treated (right-hand panels) cells treated with
ethanol (control) or Act D for two hours in cells treated with
control of U4 AMO (10 nmol). Two panels are shown per
condition. Scale bar is 15 mm.
(TIF)
Figure S5 pre-mRNA cleavage and polyadenylation are
required for the formation of enlarged speckles follow-
ing splicing inhibition. A. Alternative pictures accompanying
main text figure 6C: IF of SC35 in cells treated with control or
CPSF73 siRNAs and, subsequently, with control or U4 AMO.
Two data panels are shown. Scale bar is 5 mm. B. Poly(A)+ RNA
FISH in control and U4 AMO treated cells treated with DMSO or
the polyadenylation inhibitor cordycepin (CDY). CDY prevents
the formation of enlarged poly(A)+ speckles following U4 AMO
treatment. Scale bar is 5 mm. C. SC35 IF in control and U4 AMO
treated cells treated with DMSO or the polyadenylation inhibitor
cordycepin (CDY). CDY prevents the formation of enlarged
SC35-containing speckles following U4 AMO treatment. Scale bar
is 20 mm.
(TIF)
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